Please login to the form below

Not currently logged in
Email:
Password:

norovirus

This page shows the latest norovirus news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine. If approved the drug is anticipated to surpass sales of GSK’ s Rotarix vaccine. ... There is no drug treatment available, so management of norovirus focuses on preventing transmission and supportive care for

Latest news

  • Takeda pays $60m for vaccine company LigoCyte Takeda pays $60m for vaccine company LigoCyte

    Takeda pays $60m for vaccine company LigoCyte. Gains first-in-class norovirus candidate and new vaccine platform. ... Norovirus is responsible for a significant burden of disease around the world and is notoriously difficult to control.

  • Germinating virologists

    The aim is to exploit the expertise he has built up in generating Naked Scientist to increase public knowledge in microbiology on issues such as C difficile, norovirus and MRSA.

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    LigoCyte has a number of vaccine products in development, including its lead candidate, which is in phase I/II vaccine to prevent norovirus gastroenteritis, commonly known as winter vomiting disease.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics